Cargando…

AZD9291-induced Acute Interstitial Lung Disease

Detalles Bibliográficos
Autores principales:	Nie, Ke-Ke, Zou, Xiao, Geng, Chuan-Xin, Zhang, Ling, Liu, Shi-Chao, Zhang, Chun-Ling, Ji, You-Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910381/ https://www.ncbi.nlm.nih.gov/pubmed/27270553 http://dx.doi.org/10.4103/0366-6999.183426

Ejemplares similares

A case report of toxic epidermal necrolysis associated with AZD-9291
por: Wang, Jie, et al.
Publicado: (2018)

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2019)

Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
por: Li, Lin, et al.
Publicado: (2017)

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
por: Liu, Yutao, et al.
Publicado: (2018)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

Author Correction: AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2020)

Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
por: Wang, Nannan, et al.
Publicado: (2019)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
por: Tang, Zheng-Hai, et al.
Publicado: (2016)

Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines
por: Chen, Tianxiang, et al.
Publicado: (2019)

Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer
por: Zhu, Chao, et al.
Publicado: (2019)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
por: Liu, Xuejiao, et al.
Publicado: (2019)

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
por: Zhang, Xiao-Yu, et al.
Publicado: (2016)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Successful treatment after toxic epidermal necrolysis induced by AZD-9291 in a patient with non-small cell lung cancer: A case report
por: Li, Wen, et al.
Publicado: (2021)

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
por: Thress, Kenneth S., et al.
Publicado: (2015)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer
por: Deng, Qinfang, et al.
Publicado: (2020)

AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
por: Gu, Yu, et al.
Publicado: (2020)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
por: Wang, Junhui, et al.
Publicado: (2019)

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report
por: Chen, Jingyu, et al.
Publicado: (2022)

AZD9291-resistant non-small cell lung cancer cell-derived exosomal lnc-MZT2A-5:1 induces the activation of fibroblasts
por: Song, Liwei, et al.
Publicado: (2021)

Successful Treatment of Erlotinib on Metastatic Adenoid Cystic Carcinoma of the Lacrimal Gland
por: Nie, Ke-Ke, et al.
Publicado: (2018)

AZD-1222: Acute interstitial nephritis: case report
Publicado: (2022)

Bronchial epithelial gene expression and interstitial lung abnormalities
por: Menon, Aravind A., et al.
Publicado: (2023)

Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
por: Huang, Jing, et al.
Publicado: (2018)

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Research progress on amyopathic dermatomyositis associated with interstitial lung disease
por: Bai, Yu, et al.
Publicado: (2020)

Mining and Correlation Analysis of Association Rules between Properties and Therapeutic Efficacy of Chinese Materia Medica Based on Strategy Pattern
por: Wu, Di-Yao, et al.
Publicado: (2018)

Transbronchial Lung Cryobiopsy in Diffuse Interstitial Lung Diseases . . . Bent but Not Broken
por: Agarwal, Ritesh, et al.
Publicado: (2019)

Walking the path of treatable traits in interstitial lung diseases
por: Amati, Francesco, et al.
Publicado: (2023)

SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met
por: Tong, Mengya, et al.
Publicado: (2019)

AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal
por: Sah, Ranjit, et al.
Publicado: (2021)

Preserved Ratio Impaired Spirometry and Interstitial Lung Abnormalities in Smokers
por: Marruchella, Almerico
Publicado: (2019)

Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases: An Ongoing Tale
por: Wand, Ori, et al.
Publicado: (2020)

Interstitial lung disease-related pneumomediastinum in COVID-19 patients
por: Blanc, Kim, et al.
Publicado: (2021)

Progressive Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis
por: Rose, Jonathan A., et al.
Publicado: (2022)

Circulating Dickkof-1 as a potential biomarker associated with the prognosis of patients with rheumatoid arthritis-associated interstitial lung disease
por: Xue, Jing, et al.
Publicado: (2021)

Persistent left superior vena cava associating with anomalous right superior vena cava drainage, atrial septal defect and atrial fibrillation: a case report
por: Li, Lei, et al.
Publicado: (2019)

Successful treatment with tocilizumab in a patient with rapidly progressive interstitial lung disease with positive anti-melanoma differentiation-associated gene-5 antibody
por: Teng, Fei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_thnfqrpl7npgj3ntvb1mp520dm